Frontiers in Oncology

Article	Citations
CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future	249
Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers	205
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics	165
Chronic Stress Promotes Cancer Development	163
Mechanisms of Cancer Resistance to Immunotherapy	160
The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to Pro-tumor Activity	160
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy	157
Long Non-Coding RNAs: The Regulatory Mechanisms, Research Strategies, and Future Directions in Cancers	147
Integrated Multi-Omics Analyses in Oncology: A Review of Machine Learning Methods and Tools	137
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?	135
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions	132
Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis	126
Breast Cancer Survivorship, Quality of Life, and Late Toxicities	124
Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches	123
Boron Neutron Capture Therapy: A Review of Clinical Applications	122
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy	121
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis	119
Mutant p53 in Cancer Progression and Targeted Therapies	118
Identification and Verification of Immune-Related Gene Prognostic Signature Based on ssGSEA for Osteosarcoma	118
The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy	116
Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming	116
The role of BCL-2 family proteins in regulating apoptosis and cancer therapy	116
Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors	114
Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups	112
Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment	111

Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data	109
Artificial Convolutional Neural Network in Object Detection and Semantic Segmentation for Medical Imaging Analysis	103
Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship	101
P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers	101
Metabolic Adaptations in Cancer Stem Cells	99
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells	98
Integrated Analysis of lncRNA–Mediated ceRNA Network in Lung Adenocarcinoma	98
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies	95
Clinical and Biological Significances of a Ferroptosis-Related Gene Signature in Glioma	94
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects	94
Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib	94
Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade	93
Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model	92
IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment	92
Has COVID-19 Affected Cancer Screening Programs? A Systematic Review	90
Proline Metabolism in Tumor Growth and Metastatic Progression	90
A Review on Anti-Tumor Mechanisms of Coumarins	90
Obesity, Type 2 Diabetes, and Cancer Risk	88
Psychological Distress in Outpatients With Lymphoma During the COVID-19 Pandemic	87
IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma	87
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy	87
Ferroptosis in Cancer Treatment: Another Way to Rome	87
Sexual Dimorphism in Colon Cancer	87
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism	86
The Role of the Transcription Factor EGR1 in Cancer	85
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients	85
New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma	84
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?	84
Emerging Roles of Wnt Ligands in Human Colorectal Cancer	83
Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy	83
Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications	82
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation	82
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion	81
Global Research Trends on Prostate Diseases and Erectile Dysfunction: A Bibliometric and Visualized Study	81
Knowledge Domain and Emerging Trends in Ferroptosis Research: A Bibliometric and Knowledge-Map Analysis	80
Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies	80
A Novel Prognostic Marker Systemic Inflammation Response Index (SIRI) for Operable Cervical Cancer Patients	80
Role of DNA Methylation in the Resistance to Therapy in Solid Tumors	79
Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases	79
The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy	78
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease	78
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review	78
Sintilimab: A Promising Anti-Tumor PD-1 Antibody	76
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies	76
Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)	76
Immune Checkpoint Inhibitors in the Treatment of HCC	75
Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters	75
A Review of Newly Diagnosed Glioblastoma	73
RETRACTED: The Oncolytic Virus in Cancer Diagnosis and Treatment	73
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment	73

Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer	72
FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis	72
m6A Reader HNRNPA2B1 Promotes Esophageal Cancer Progression via Up-Regulation of ACLY and ACC1	71
Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status	71
EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives	71
Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review	71
Lactate Modulates Cellular Metabolism Through Histone Lactylation-Mediated Gene Expression in Non-Small Cell Lung Cancer	71
Osteosarcoma and Metastasis	71
Cysteine Depletion, a Key Action to Challenge Cancer Cells to Ferroptotic Cell Death	70
Tumor Associated Macrophages: Origin, Recruitment, Phenotypic Diversity, and Targeting	70
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer	70
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review	70
CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment	69
MYCN Function in Neuroblastoma Development	69
The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer	69
Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment	69
An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma	68
Humanized Rodent Models for Cancer Research	68
The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer	68
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer	68
Cancer in Africa: The Untold Story	68
RNA-Seq Profiling of Serum Exosomal Circular RNAs Reveals Circ-PNN as a Potential Biomarker for Human Colorectal Cancer	67
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics	67
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents	67
RETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy	67
The role of IL-6/JAK2/STAT3 signaling pathway in cancers	66
Systemic Reprogramming of Monocytes in Cancer	66
Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine	66
The Landscape of Immune Cells Infiltrating in Prostate Cancer	65
Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy	65
YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy	65
Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease	65
Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma	64
The Mevalonate Pathway, a Metabolic Target in Cancer Therapy	64
Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance	64
The Metabolic Mechanisms of Breast Cancer Metastasis	64
Genome-Wide Sex and Gender Differences in Cancer	64
FLASH Radiotherapy: History and Future	63
From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment	63
Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma	63
Immunotherapy in Acute Myeloid Leukemia: Where We Stand	63
Meningioma: A Review of Clinicopathological and Molecular Aspects	63
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives	61
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions	61
Targeted Therapies and Biomarkers in Small Cell Lung Cancer	61
Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer	61
Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells	61
The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology	60
Pyroptosis-Related Gene Signatures Can Robustly Diagnose Skin Cutaneous Melanoma and Predict the Prognosis	60
Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review	60
Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk	60
A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis	60
5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent	60
Reciprocal Interplay Between Fibrillar Collagens and Collagen-Binding Integrins: Implications in Cancer Progression and Metastasis	60
CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences	60
Targeting CXCR4 in AML and ALL	60
LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer	59
The Role of CD276 in Cancers	59
Artificial Intelligence (AI)-Based Systems Biology Approaches in Multi-Omics Data Analysis of Cancer	59
Patient-Derived Cancer Organoids as Predictors of Treatment Response	59
m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma	59
The Role of Iron in Cancer Progression	59
Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer	59
Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor	59
A Potential Role of YAP/TAZ in the Interplay Between Metastasis and Metabolic Alterations	59
Identification of Hub Genes Associated With Development of Head and Neck Squamous Cell Carcinoma by Integrated Bioinformatics Analysis	58
Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers	58
Induction of Pyroptosis: A Promising Strategy for Cancer Treatment	58
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy	58
PPAR-α Modulators as Current and Potential Cancer Treatments	58
Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine	58
The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2017	57
Extracellular Matrix Stiffness: New Areas Affecting Cell Metabolism	57
Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy	57
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank	57
Inhibition of Fatty Acid Synthase Upregulates Expression of CD36 to Sustain Proliferation of Colorectal Cancer Cells	57
Probiotics in Cancer	56
LncRNA-Encoded Peptide: Functions and Predicting Methods	56
Dysregulated m6A-Related Regulators Are Associated With Tumor Metastasis and Poor Prognosis in Osteosarcoma	56
Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma	56

The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development	56
Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis	56
Immunosuppression in Glioblastoma: Current Understanding and Therapeutic Implications	56
Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments	56
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy	56
Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer	55
Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia	55
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma	55
68Ga-FAPI-04 Versus 18F-FDG PET/CT in the Detection of Hepatocellular Carcinoma	55
Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?	55
MR-Guided Radiotherapy for Prostate Cancer	55
Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy	55
Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?	55
Primary Cutaneous B-Cell Lymphomas: An Update	55
A Review on Application of Deep Learning Algorithms in External Beam Radiotherapy Automated Treatment Planning	54
Targeting Lysosomes in Cancer as Promising Strategy to Overcome Chemoresistance—A Mini Review	54
Radiation Resistance: A Matter of Transcription Factors	54
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors	54
Cholesterol Metabolic Reprogramming in Cancer and Its Pharmacological Modulation as Therapeutic Strategy	54
VCAM1 Promotes Tumor Cell Invasion and Metastasis by Inducing EMT and Transendothelial Migration in Colorectal Cancer	54
The Lipid Metabolic Landscape of Cancers and New Therapeutic Perspectives	54
Identification of a Ferroptosis-Related LncRNA Signature as a Novel Prognosis Model for Lung Adenocarcinoma	53
Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma	53
GLI1: A Therapeutic Target for Cancer	52
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer	52
Starting a Fire Without Flame: The Induction of Cell Death and Inflammation in Electroporation-Based Tumor Ablation Strategies	52
Actors on the Scene: Immune Cells in the Myeloma Niche	52
Understanding Sources of Variation to Improve the Reproducibility of Radiomics	52
Integration of scRNA-Seq and Bulk RNA-Seq to Analyse the Heterogeneity of Ovarian Cancer Immune Cells and Establish a Molecular Risk Model	52
Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer	51
Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer	51
Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs)	51
Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities	51
Platelets and Metastasis: New Implications of an Old Interplay	51
Acetyl-CoA Carboxylases and Diseases	51
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade	51
Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues	51
A Deep Multi-Task Learning Framework for Brain Tumor Segmentation	51
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?	50
A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma	50
Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses	50
Application of a 3D Bioprinted Hepatocellular Carcinoma Cell Model in Antitumor Drug Research	50
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?	50
Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers	50
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions	50
Emerging Role of Circular RNAs in Cancer	50
m6A Reader YTHDC2 Promotes Radiotherapy Resistance of Nasopharyngeal Carcinoma via Activating IGF1R/AKT/S6 Signaling Axis	50
CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment	50
Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review	49
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade	49
The PDAC Extracellular Matrix: A Review of the ECM Protein Composition, Tumor Cell Interaction, and Therapeutic Strategies	49
The Role of Non-Coding RNAs in Controlling Cell Cycle Related Proteins in Cancer Cells	49
Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment	49
Tumor-Associated Macrophages: A Potential Target for Cancer Therapy	49
Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study	49
Circular RNA HIPK3: A Key Circular RNA in a Variety of Human Cancers	49
PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis	49
The Implications of PDK1–4 on Tumor Energy Metabolism, Aggressiveness and Therapy Resistance	49
Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis	49
High Expression of FAP in Colorectal Cancer Is Associated With Angiogenesis and Immunoregulation Processes	48
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies	48
The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer	48
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer	48
Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer	48
Dysbiosis of Oral Microbiota During Oral Squamous Cell Carcinoma Development	48
Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers	48
An Original Ferroptosis-Related Gene Signature Effectively Predicts the Prognosis and Clinical Status for Colorectal Cancer Patients	48
Review on the Cellular Mechanisms of Low-Level Laser Therapy Use in Oncology	48
Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges	47
pH-Responsive Polymer Nanomaterials for Tumor Therapy	47
The Role of the ECM in Lung Cancer Dormancy and Outgrowth	47
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies	47
Establishment and Initial Experience of Clinical FLASH Radiotherapy in Canine Cancer Patients	47
Prognosis Analysis and Validation of m6A Signature and Tumor Immune Microenvironment in Glioma	47
Proteomic Profiling of Serum Exosomes From Patients With Metastatic Gastric Cancer	47
The Resistance Mechanisms of Lung Cancer Immunotherapy	47
The Dual Role of Macropinocytosis in Cancers: Promoting Growth and Inducing Methuosis to Participate in Anticancer Therapies as Targets	47
Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy	46
Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma	46
Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?	46
The Role of EBV-Encoded LMP1 in the NPC Tumor Microenvironment: From Function to Therapy	46
Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy	46
Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model	46
In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China	46
Deep Learning With Radiomics for Disease Diagnosis and Treatment: Challenges and Potential	46
One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma	46
Feasibility of Prehabilitation Prior to Breast Cancer Surgery: A Mixed-Methods Study	45
Lobular Breast Cancer: A Review	45
Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies	45
High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions	45
The Antitumor Effect of Gene-Engineered Exosomes in the Treatment of Brain Metastasis of Breast Cancer	45
Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer	45
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives	45
Association Between Night-Shift Work and Cancer Risk: Updated Systematic Review and Meta-Analysis	45
Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges	45